1. De novo PMP2 mutations in families with type 1 CharcotMarieTooth disease
- Author
-
Albena Jordanova, Alleene V. Strickland, Sabrina W. Yum, Stefan Koppi, Michael A. Gonzalez, Andreas R. Janecke, Wolfgang Löscher, Els De Vriendt, Feifei Tao, Stephan Züchner, Paulius Palaima, William W. Motley, Steven S. Scherer, Livija Medne, and Julia Wanschitz
- Subjects
Male ,0301 basic medicine ,Proband ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Neural Conduction ,Disease ,Myelin P2 Protein ,medicine.disease_cause ,Young Adult ,03 medical and health sciences ,Myelin ,0302 clinical medicine ,Charcot-Marie-Tooth Disease ,medicine ,Humans ,Exome ,Genetic Predisposition to Disease ,Gene ,Exome sequencing ,Genetics ,Mutation ,business.industry ,PMP2 ,Middle Aged ,medicine.disease ,Pedigree ,030104 developmental biology ,Peripheral neuropathy ,medicine.anatomical_structure ,Haplotypes ,Female ,Neurology (clinical) ,Human medicine ,business ,030217 neurology & neurosurgery ,Reports - Abstract
We performed whole exome sequencing on a patient with CharcotMarieTooth disease type 1 and identified a de novo mutation in PMP2, the gene that encodes the myelin P2 protein. This mutation (p.Ile52Thr) was passed from the proband to his one affected son, and segregates with clinical and electrophysiological evidence of demyelinating neuropathy. We then screened a cohort of 136 European probands with uncharacterized genetic cause of CharcotMarieTooth disease and identified another family with CharcotMarieTooth disease type 1 that has a mutation affecting an adjacent amino acid (p.Thr51Pro), which segregates with disease. Our genetic and clinical findings in these kindred demonstrate that dominant PMP2 mutations cause CharcotMarieTooth disease type 1.
- Published
- 2016